FRANKLIN LAKES, N.J.,
Sept. 30, 2016 /PRNewswire/
-- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading
global medical technology company, today announced the launch of
its next generation diagnostic instrument for the rapid
identification of bacteria and detection of antimicrobial
resistance.
The global health care community is facing unprecedented
challenges with the spread of multidrug resistant organisms, and
today's clinical microbiology laboratories are under increasing
pressure to provide fast and accurate bacterial identification and
antimicrobial susceptibility testing (ID/AST) results to
influence clinical decision and outcomes.
The new BD Phoenix™ M50 ID/AST system helps deliver the same
rapid, accurate and cost-effective testing as the legacy BD
Phoenix™ 100, within a smaller footprint. The system is highly
reliable and requires no preventative maintenance, thanks to
innovative materials and engineering techniques employed during its
development. In addition to being robust, the system offers
multiple languages, facilitating even broader adoption in
laboratories around the world.
The new system benefits from the demonstrated performance of the
legacy BD Phoenix 100 system for detecting current and emerging
resistances as well as the extended testing capabilities provided
by BD Phoenix™ Emerge AST panel with 136 wells.
The BD Phoenix M50 system also offers integration with multiple
other analyzers, including the BD BACTEC™ and BD Bruker™ MALDI
Biotyper systems, through BD EpiCenter™ middleware connectivity
that enables data traceability and security, paperless workflow and
flexible communication capabilities to deliver the efficiencies
expected by laboratories of all sizes. The BD Phoenix M50
system joins the overall BD diagnostics portfolio to help drive the
transformation of microbiology.
"The small footprint of the BD Phoenix M50 system combined with
its demonstrated speed, accuracy and efficiency makes the system an
attractive solution for microbiology laboratories around the
world," said Dave Hickey, president
of Diagnostics Systems for BD. "This launch reinforces the
engagement of BD to become more relevant in ID/AST and intensifies
its support to the fight against antimicrobial resistance."
Visit bd.com/ds for more information.
About BD
BD is a global medical technology company that is advancing the
world of health by improving medical discovery, diagnostics and the
delivery of care. BD leads in patient and health care worker safety
and the technologies that enable medical research and clinical
laboratories. The company provides innovative solutions that help
advance medical research and genomics, enhance the diagnosis of
infectious disease and cancer, improve medication management,
promote infection prevention, equip surgical and interventional
procedures, optimize respiratory care and support the management of
diabetes. The company partners with organizations around the world
to address some of the most challenging global health issues. BD
has more than 45,000 associates across 50 countries who work in
close collaboration with customers and partners to help enhance
outcomes, lower health care delivery costs, increase efficiencies,
improve health care safety and expand access to health. For more
information on BD, please visit bd.com.
Contacts:
|
|
|
|
|
Troy
Kirkpatrick
|
|
|
|
Monique N.
Dolecki
|
BD Public
Relations
|
|
|
|
BD Investor
Relations
|
858.617.2361
|
|
|
|
201.847.5378
|
troy.kirkpatrick@bd.com
|
|
|
|
monique_dolecki@bd.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bd-expands-efforts-to-combat-antimicrobial-resistance-with-new-automated-idast-system-300337155.html
SOURCE BD (Becton, Dickinson and Company)